Zimmer Biomet initiated with a Market Perform at Leerink

Leerink initiated coverage of Zimmer Biomet (ZBH) with a Market Perform rating and $10 price target While the shares are trading at a discount to its large-cap medical technology peers and its historical relative valuation levels, Zimmer’s risk/reward is balanced, the analyst tells investors in a research note. The firm sees limited near-term upside ahead of the company’s “more meaningful” catalysts in 2027. Zimmer’s near-term growth is “sensitive” to ongoing market share shifts and pricing, which could limit the degree of potential upside versus expectations, contends Leerink.